Song Juxian, Wang Yu, Ma Kuansheng, Zheng Shuguo, Bie Ping, Xia Feng, Li Xiaowu, Li Jianwei, Wang Xiaojun, Chen Jian
Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Gaotanyan Main Street 29, Shapingba District, Chongqing, 400038, China.
Surg Endosc. 2016 Oct;30(10):4249-57. doi: 10.1007/s00464-015-4737-1. Epub 2015 Dec 29.
There is currently no clear consensus on the relative suitabilities of laparoscopic hepatectomy (LH) and radiofrequency ablation (RFA) as minimally invasive treatment for small hepatocellular carcinoma (HCC).
In this retrospective study, we enrolled 156 patients with a single, small HCC with nodular diameters <4 cm and compared recurrence-free survival (RFS) and overall survival (OS) between patients treated with LH and control patients treated with RFA (n = 78 each). The groups were selected according to predefined criteria and matched in terms of their baseline clinical characteristics.
During a median follow-up of 31.2 months, the 1-, 2-, and 3-year OS rates in the LH group were 96.2, 91.3, and 84.1 %, respectively, compared with 96.2, 82.6, and 78.8 % in the RFA group. The corresponding RFS rates were 82.1, 71.5, and 60.0 % in the LH group and 65.4, 47.7, and 37.6 % in the RFA group. Combined RFS rates were significantly higher in the LH groups (P = 0.006), but there was no significant difference in OS rates (P = 0.510). The incidence of postoperative complications was significantly lower in the RFA group (28.2 vs. 10.3 %, P = 0.004), and operation duration, intraoperative blood loss and blood transfusion, use of total parenteral nutrition, and length of stay as indicators of minimal invasiveness were also significantly better in the RFA group.
There was no difference between LH and RFA in terms of OS in patients with a single, small HCC. However, RFA was less invasive than the LH, but LH was associated with increased RFS.
目前,对于腹腔镜肝切除术(LH)和射频消融术(RFA)作为小肝细胞癌(HCC)微创治疗的相对适用性尚无明确共识。
在这项回顾性研究中,我们纳入了156例单发小HCC患者,结节直径<4 cm,并比较了接受LH治疗的患者与接受RFA治疗的对照患者(每组n = 78)的无复发生存期(RFS)和总生存期(OS)。根据预先定义的标准选择研究组,并使其基线临床特征相匹配。
在中位随访31.2个月期间,LH组的1年、2年和3年OS率分别为96.2%、91.3%和84.1%,而RFA组分别为96.2%、82.6%和78.8%。LH组相应的RFS率分别为82.1%、71.5%和60.0%,RFA组分别为65.4%、47.7%和37.6%。LH组的联合RFS率显著更高(P = 0.006),但OS率无显著差异(P = 0.510)。RFA组术后并发症的发生率显著更低(28.2%对10.3%,P = 0.004),并且以手术时间、术中失血量和输血量、全胃肠外营养的使用以及住院时间作为微创指标,RFA组也显著更好。
对于单发小HCC患者,LH和RFA在OS方面无差异。然而,RFA的侵入性低于LH,但LH与更高的RFS相关。